Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B7c02156c30be6770da1fa70ffc665b1e> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B7c02156c30be6770da1fa70ffc665b1e NCIT_P378 "NCI" @default.
- B7c02156c30be6770da1fa70ffc665b1e type Axiom @default.
- B7c02156c30be6770da1fa70ffc665b1e annotatedProperty IAO_0000115 @default.
- B7c02156c30be6770da1fa70ffc665b1e annotatedSource NCIT_C114293 @default.
- B7c02156c30be6770da1fa70ffc665b1e annotatedTarget "A dendritic cell (DC)-based cancer vaccine composed of autologous, type-1 polarized dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted HER-2-derived peptides, with potential immunomodulatory and antineoplastic activities. Autologous DCs were treated with GM-CSF, interleukin-4, interferon-gamma and bacterial lipopolysaccharide (LPS), a toll-like receptor type 4 agonist, to produce highly polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). Upon administration, HER2-pulsed autologous DC vaccine may stimulate a potent cytotoxic T-lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by a variety of cancers." @default.